PULSAR Results and Their Relation to nAMD Patients in Your Practice

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice. They touch upon dosing strategies and also highlight two new drugs, faricimab and aflibercept 8 mg. They also discuss the potential benefits of increased molar dosing and the importance of maintaining dryness and durability in patient care.

See the key takeaways below, and listen to the full podcast for all the clinical pearls.

Drug dosing and half-life in retina treatment.

• Highlighting developments in ocular drug delivery, including new formulations of existing drugs and potential challenges in the clinic.
• Discussing increased molar dosing of aflibercept.
• Explaining the variability in patient clearance rates and their impact on treatment outcomes.

Aflibercept 8 mg, including study findings and clinical practice applications.

• Clinical practice for aflibercept dosing, including loading doses and extension intervals.
• Prioritising individualised approach based on patient's response and disease activity.

The safety and efficacy of a drug for treating retinal diseases.

• Extending drug treatment from 8 weeks and onward with positive patient response.
• Safety data and potential label change with regulatory agencies.
• The importance of manufacturing processes and the challenges of creating fully human antibodies to VEGF.